Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens. Results of the Phase 2, open-label study indicate the antibody, known as UB-421, was safe and did not induce the production of antibody-resistant HIV.
from All Top News -- ScienceDaily https://www.sciencedaily.com/releases/2019/04/190417171048.htm
from All Top News -- ScienceDaily https://www.sciencedaily.com/releases/2019/04/190417171048.htm
Comments
Post a Comment
Thank you for your message. We are improving our services everyday.